PKD1/2/3/PKC u (Phospho-Ser738/742) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-PKD1/2/3/PKC u (Phospho-Ser738/742) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityPKD1/2/3/PKC u (Phospho-Ser738/742)
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman, mouse, rat
Isotypen/a
Formatepitope affinity purified
Size0.05 mL, 0.1 mL
Concentration1.0 mg/ml
ApplicationsWestern Blot (WB)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe antibody detects endogenous level of PKD1/2/3/PKC mu only when phosphorylated at Serine 738/742. Serine/threonine-protein kinase that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC, and is involved in the regulation of MAPK8/JNK1 and Ras signaling, Golgi membrane integrity and trafficking, cell survival through NF-kappa-B activation, cell migration, cell differentiation by mediating HDAC7 nuclear export, cell proliferation via MAPK1/3 (ERK1/2) signaling, and plays a role in cardiac hypertrophy, VEGFA-induced angiogenesis, genotoxic-induced apoptosis and flagellin-stimulated inflammatory response. Phosphorylates the epidermal growth factor receptor (EGFR) on dual threonine residues,
ImmunogenImmunogen Type: Peptide-KLH Immunogen Description: Peptide sequence around phosphorylation site of Serine738/Serine 742
Other Names[PKD, PKCM, PRKCM, PKC-MU]
Gene, Accession #[PKD1/2/3/PKC u], Gene ID: 5587, NCBI: NP_002733.2, UniProt: Q15139
Catalog #MBS9414438
Price$200, $255
Order / More InfoPKD1/2/3/PKC u (Phospho-Ser738/742) Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.